Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheila A Doggrell

Showing results (131-140 of 220) with videos related to

Pageof 22
Sort By:
Expert Opinion on Investigational Drugs|July 30, 2005
Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|August 10, 2005
Relating statin therapy to C-reactive protein levelsSheila A Doggrell
International Journal of Clinical Pharmacy|May 10, 2013
Inadequate management of medicines by the older-aged living in a retirement villageSheila A Doggrell
Patient Preference and Adherence|January 24, 2013
Exenatide extended-release; clinical trials, patient preference, and economic considerationsSheila A Doggrell
Drugs & Aging|March 10, 2010
Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|September 21, 2018
Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?Sheila A Doggrell
Expert Review of Endocrinology & Metabolism|October 10, 2018
Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONYSheila A Doggrell
Reviews on Recent Clinical Trials|April 18, 2015
After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|May 31, 2006
Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|June 15, 2007
Clopidogrel use with stentingSheila A Doggrell
Pageof 22

Showing results (131-140 of 220) with videos related to

Sort By:
Pageof 22
Expert Opinion on Investigational Drugs|July 30, 2005
Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|August 10, 2005
Relating statin therapy to C-reactive protein levelsSheila A Doggrell
International Journal of Clinical Pharmacy|May 10, 2013
Inadequate management of medicines by the older-aged living in a retirement villageSheila A Doggrell
Patient Preference and Adherence|January 24, 2013
Exenatide extended-release; clinical trials, patient preference, and economic considerationsSheila A Doggrell
Drugs & Aging|March 10, 2010
Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|September 21, 2018
Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?Sheila A Doggrell
Expert Review of Endocrinology & Metabolism|October 10, 2018
Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONYSheila A Doggrell
Reviews on Recent Clinical Trials|April 18, 2015
After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|May 31, 2006
Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|June 15, 2007
Clopidogrel use with stentingSheila A Doggrell
Pageof 22